ReCor Medical, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ReCor Medical, Inc.
The company announced that results from the pivotal SPYRAL HTN-ON MED trial of its Symplicity renal denervation system will not be available until the trial completes enrollment next year. The company previously expected to be able to present favorable interim results from the trial in November.
April and May were full of cardiovascular professional society conferences, yielding important new research results along with announcements of major new clinical trials. Here are a few of the highlights.
In an unprecedented move, eight of India’s top pharma companies, including Sun Pharma, Cipla, Torrent and Lupin, have set up a common vehicle for digitization initiatives. Having acquired local market research firm AIOCD AWACS and B2B platform Pharmarack, could the mandate extend to other services?
Medtech Insight's Results Recap is a regular feature covering the major device trial results compiled by MedDeviceTracker. This is the third of three Results Recaps covering trial data presented at the American College of Cardiology Scientific Sessions in New Orleans, March 16-18, including the final results of the MOMENTUM 3 trial of Abbott’s HeartMate 3 left-ventricular assist device and six-month results from the RADIANCE-HTN SOLO trial of ReCor’s Paradise renal denervation system, and more. Check out Part I and Part II of our ACC Results Recap.